proteolyt
cleavag
regul
numer
process
health
diseas
one
key
player
ubiquit
express
serin
proteas
furin
cleav
plethora
protein
polybas
recognit
motif
mammalian
substrat
furin
includ
cytokin
hormon
growth
factor
receptor
thu
surpris
aberr
furin
activ
associ
varieti
disord
includ
cancer
furthermor
enzymat
activ
furin
exploit
numer
viral
bacteri
pathogen
therebi
enhanc
virul
spread
review
describ
physiolog
pathophysiolog
substrat
furin
discuss
dysregul
simpl
proteolyt
cleavag
event
may
promot
infecti
diseas
cancer
one
major
focu
role
furin
viral
glycoprotein
matur
pathogen
also
outlin
cellular
mechan
regul
express
activ
furin
summaris
current
approach
target
proteas
therapeut
intervent
human
genom
encod
proteas
molecular
scissor
play
import
role
essenti
physiolog
process
digest
protein
food
degrad
misfold
unwant
protein
regul
traffick
activ
numer
cellular
factor
proteolyt
cleavag
certainli
one
import
posttransl
modif
gener
plethora
bioactiv
protein
peptid
key
role
cell
prolifer
immun
inflamm
surprisingli
mutat
proteas
andor
aberr
proteas
activ
associ
numer
patholog
process
includ
cancer
cardiovascular
disord
autoimmun
diseas
intriguingli
also
mani
viral
pathogen
exploit
cellular
proteas
proteolyt
process
matur
protein
similarli
activ
bacteri
toxin
frequent
requir
cleavag
proteas
infect
intox
host
recent
year
modul
proteas
activ
therefor
emerg
potenti
therapeut
approach
varieti
infecti
noninfecti
diseas
one
particularli
promis
target
therapeut
intervent
cellular
proteas
furin
proteas
like
cleav
activ
mammalian
viral
bacteri
substrat
among
viral
envelop
glycoprotein
bacteri
toxin
well
cellular
factor
promot
tumor
develop
growth
hyperactiv
figur
review
summaris
current
knowledg
furinmedi
protein
process
health
diseas
focu
role
furin
viral
protein
process
furthermor
describ
cellular
mechan
regul
furin
activ
transcript
posttranscript
level
final
present
approach
aim
modul
furin
activ
therapeut
purpos
discuss
suitabl
clinic
applic
furin
member
evolutionarili
ancient
famili
proprotein
convertas
similar
bacteri
subtilisin
yeast
kexin
proteas
coin
abbrevi
pcsk
proprotein
convertas
subtilisinkexin
type
human
encod
nine
member
proteas
famili
repres
furin
tabl
pcsk
well
known
abil
activ
cellular
protein
proteolyt
convers
inact
precursor
protein
bioactiv
molecul
alreadi
describ
howev
took
year
furin
identifi
first
mammalian
proprotein
convertas
date
cellular
substrat
pcsk
describ
includ
hormon
receptor
growth
factor
adhes
molecul
although
pcsk
frequent
coexpress
cell
may
cleav
substrat
complet
redund
inactiv
individu
pcsk
result
specif
knockout
phenotyp
mice
cleav
substrat
basic
residu
typic
recognit
motif
krx
n
tabl
contrast
cleav
nonbas
residu
best
known
regul
cholesterol
lipid
metabol
activ
sterol
regulatori
elementbind
protein
srebp
transcript
factor
like
also
play
key
role
cholesterol
metabol
regul
lowdens
lipoprotein
ldl
particl
level
blood
howev
effect
involv
proteolyt
cleavag
specif
substrat
mediat
direct
bind
ldl
receptor
two
fdaapprov
inhibitor
treatment
hypercholesterolaemia
also
prime
exampl
proteas
success
target
therapi
prototyp
bestcharacteris
member
pcsk
famili
sinc
cleav
basic
amino
acid
motif
also
term
pace
pair
basic
amino
acid
cleav
enzym
furin
express
fur
fe
upstream
region
gene
chromosom
although
furin
ubiquit
express
mrna
protein
level
vari
depend
cell
type
tissu
high
level
found
salivari
gland
liver
bone
marrow
wherea
muscl
cell
express
rel
low
amount
furin
three
promot
harbour
altern
transcript
start
site
describ
figur
howev
respect
transcript
differ
first
untransl
exon
therefor
predict
express
protein
promot
resembl
constitut
express
housekeep
gene
promot
bind
transcript
factor
cebpb
transactiv
upon
cytokin
stimul
line
ifnc
tgfb
pma
induc
furin
express
upon
translat
mrna
furin
enter
secretori
pathway
inact
proenzym
integr
er
membran
via
ctermin
transmembran
domain
figur
like
type
transmembran
protein
harbour
short
ntermin
signal
peptid
cleav
cotransl
similar
proprotein
convertas
furin
contain
inhibitori
ntermin
acid
propeptid
whose
chaperon
function
requir
correct
fold
catalyt
domain
transit
furin
er
transgolgi
network
tgn
inhibitori
propeptid
remov
twostep
autoproteolyt
process
furin
gain
enzymat
activ
time
nlink
oligosaccharid
ad
trim
although
furin
accumul
tgn
transport
cell
surfac
back
via
endosom
pathway
final
furin
also
shed
releas
extracellular
space
upon
proteolyt
separ
catalyt
domain
membranebound
c
terminu
whether
cleavag
step
mediat
furin
anoth
proteas
remain
determin
presenc
furin
tgn
endosom
compart
cell
surfac
extracellular
space
may
explain
abil
process
larg
varieti
intraand
extracellular
substrat
canon
furin
cleavag
site
frequent
describ
howev
variat
motif
may
also
recognis
stretch
amino
acid
surround
cleavag
site
well
posttransl
modif
determin
interact
furin
bind
pocket
bioinformat
analys
function
studi
uncov
furin
cleavag
site
mammalian
protein
compris
growth
factor
cytokin
eg
tgfb
pdgfa
pdgfb
vegfc
ngf
hormon
eg
pth
trh
ghrh
adhes
molecul
eg
integrin
vitronectin
collagen
metalloproteinas
coagul
factor
receptor
membran
channel
albumin
target
factor
activ
upon
furinmedi
cleavag
furin
also
exert
inactiv
cleavag
step
exampl
furin
paralogu
endotheli
lipas
inactiv
furin
matur
cellular
proteas
furin
furin
express
driven
three
differ
promot
share
characterist
either
cytokineactiv
housekeep
gene
promot
translat
furin
integr
er
membran
glycosyl
ntermin
signal
peptid
red
remov
autocatalyt
cleavag
event
occur
gener
short
propeptid
light
blue
propeptid
remain
associ
furin
act
intramolecular
chaperon
inhibitor
transit
golgi
complex
propeptid
remov
glycan
trim
furin
gain
proteolyt
activ
furin
accumul
transgolgi
network
tgn
also
traffic
plasma
membran
cycl
two
compart
via
endosom
proteolyt
cleavag
c
terminu
furin
separ
transmembran
domain
orang
catalyt
activ
domain
result
furin
shed
extracellular
space
activ
enzym
physiolog
import
furin
reflect
furin
knockout
mice
die
embryon
day
cardial
ventral
closur
defect
hemodynam
insuffici
similarli
endotheli
cellspecif
knockout
furin
result
cardiac
malform
death
shortli
birth
even
mutat
cleavag
site
singl
furin
target
protein
may
detriment
effect
result
genet
disord
haemophilia
b
xlink
hypohidrot
ectoderm
dysplasia
pleiotrop
effect
variat
furin
express
level
andor
enzymat
activ
may
detriment
effect
promot
pathogenesi
varieti
disord
includ
rheumatoid
arthriti
amyloid
dementia
cancer
furin
term
master
switch
tumor
growth
progress
aberr
express
activ
promot
format
progress
variou
malign
includ
colon
carcinoma
rhabdomyosarcoma
head
neck
cancer
lung
skin
brain
tumor
case
furin
level
posit
correl
aggress
increas
furin
express
propos
prognost
marker
advanc
cancer
oncogen
prometastat
activ
furin
ascrib
abil
activ
protein
promot
cell
prolifer
angiogenesi
migrat
tissu
invas
exampl
furin
cleav
activ
growth
factor
igf
pdgf
ngf
enhanc
cell
prolifer
consequ
tumor
growth
similarli
angiogen
lymphangiogen
factor
vegfc
vegfd
may
hyperactiv
promot
vascularis
growth
solid
tumor
notabl
furin
express
induc
hypoxia
three
fur
promot
harbour
bind
site
hypoxiainduc
thu
furinmedi
vascularis
may
preferenti
occur
otherwis
growthrestrict
hypox
tumor
interestingli
hypoxia
also
result
subcellular
relocalis
furin
cell
surfac
may
enhanc
process
growth
factor
extracellular
tumorigen
precursor
protein
besid
effect
tumor
growth
furin
also
promot
migrat
extravas
malign
cell
process
adhes
molecul
mediat
cellcel
cellmatrix
interact
cleavag
integrin
may
particularli
relev
mediat
adhes
cell
extracellular
matrix
also
act
signal
transduc
regul
cell
growth
divis
surviv
addit
furin
activ
matrix
metalloproteinas
eg
facilit
metastasi
degrad
compon
extracellular
matrix
final
increas
furin
activ
may
also
promot
cancer
develop
suppress
protect
antitumor
mechan
exampl
increas
furinmedi
activ
tgfb
reduc
immun
surveil
promot
develop
suppress
reg
cell
inhibit
effector
tcell
function
key
role
furin
immun
highlight
tcellspecif
furin
knockout
mice
harbour
inher
overreact
effector
cell
secret
reduc
level
activ
tgfb
notabl
posit
feedback
loop
enhanc
oncogen
potenti
furin
exampl
furin
substrat
tgfb
increas
furin
mrna
express
also
enhanc
proteolyt
activ
unknown
mechan
similarli
furin
enhanc
secret
ifnc
turn
activ
fur
promot
mutual
enhanc
seem
particularli
import
given
key
role
ifnc
tumor
develop
progress
one
hand
furindriven
ifnc
releas
may
benefici
effect
boost
tumorlyt
activ
natur
killer
cell
cytotox
lymphocyt
furthermor
ifnc
may
act
antiangiogen
factor
directli
inhibit
tumor
cell
prolifer
induc
express
tumor
suppressor
hand
howev
recent
evid
suggest
ifnc
may
also
exert
tumorpromot
effect
exampl
select
immun
evas
phenotyp
promot
immunosuppress
tumor
microenviron
intriguingli
studi
laryng
cancer
patient
suggest
ifncfurin
feedback
loop
may
boost
iatrogen
sinc
radiotherapi
increas
furin
express
patient
summari
aberr
furin
activ
promot
sever
step
cancer
develop
includ
cell
prolifer
vascularis
metastasi
antitumor
immun
howev
rel
contribut
individu
furin
substrat
tumor
progress
role
proprotein
convertas
remain
larg
unclear
furin
may
promot
diseas
upon
aberr
express
also
activ
varieti
pathogenderiv
protein
one
exampl
cleavag
unwant
protein
proteolyt
activ
bacteri
toxin
particularli
group
ab
toxin
compris
sever
welldescrib
furin
substrat
exotoxin
secret
bacteria
exert
effect
cytoplasm
target
cell
usual
consist
enzymat
activ
subunit
b
subunit
mediat
membran
bind
transloc
exert
toxic
effect
subunit
separ
membraneassoci
b
subunit
proteolyt
cleavag
case
diphtheria
toxin
pseudomona
exotoxin
furin
cleav
target
sequenc
respect
cleavag
like
occur
endosom
subunit
transloc
nucleu
inhibit
protein
synthesi
inhibit
elong
factor
line
import
role
furin
bacteri
virul
toxic
highest
optim
furin
cleavag
site
present
similarli
furin
cleav
shiga
shigalik
toxin
express
certain
shigella
spp
escherichia
coli
strain
enhanc
abil
halt
protein
synthesi
although
furin
target
sequenc
conserv
among
shigalik
toxin
mutat
analys
suggest
furinmedi
cleavag
augment
toxin
activ
essenti
anoth
wellcharacteris
exampl
anthrax
toxin
threeprotein
exotoxin
consist
receptor
bind
protect
antigen
pa
enzymat
activ
compon
oedema
factor
ef
lethal
factor
lf
upon
bind
receptor
pa
cleav
furin
cell
surfac
cleavag
step
trigger
oligomeris
pa
prepor
bind
ef
lf
subsequ
toxin
complex
endocytos
pa
form
channel
allow
transloc
ef
lf
cytoplasm
although
pa
activ
differ
proprotein
convertas
famili
member
furin
seem
major
proteas
activ
anthrax
toxin
exampl
illustr
sever
bacteri
pathogen
exploit
furin
relat
convertas
activ
exotoxin
strictli
speak
howev
toxin
produc
bacteria
eg
diphtheria
toxin
shiga
toxin
repres
viral
gene
product
encod
bacteriophag
case
term
viral
exotoxin
may
appropri
strongli
suggest
furinmedi
toxin
activ
confer
select
advantag
bacterium
phage
exampl
induct
cell
death
furinactiv
toxin
may
promot
tissu
invas
increas
transmiss
rate
eg
caus
diarrhoea
suppress
cellular
immun
respons
without
proteolyt
activ
exotoxin
diseas
dysenteri
diphtheria
would
occur
like
bacteri
viral
exotoxin
viral
envelop
glycoprotein
need
proteolyt
cleav
mediat
viral
entri
host
cell
mani
case
virus
exploit
cellular
trypsinor
subtilisinlik
endoproteas
purpos
subtilisinlik
proteas
furin
requir
polybas
cleavag
site
trypsinlik
proteas
also
recognis
monobas
motif
cleav
singl
arginin
lysin
residu
notabl
depend
specif
proteas
also
import
determin
tissu
tropism
viral
spread
infect
organ
exampl
avirul
newcastl
diseas
viru
ndv
strain
harbour
monobas
cleavag
site
fusion
f
protein
result
local
infect
mainli
respiratori
tract
sinc
express
respect
host
proteas
limit
cell
type
contrast
f
protein
virul
ndv
strain
cleav
furin
relat
proprotein
convertas
ubiquit
express
consequ
virus
abl
spread
system
caus
high
rate
mortal
infect
bird
anoth
welldescrib
exampl
cleavag
influenza
viru
hemagglutinin
ha
contrast
low
pathogen
avian
influenza
virus
highli
pathogen
counterpart
harbour
polybas
furin
cleavag
site
ha
protein
thu
abil
virus
exploit
furin
may
drastic
effect
pathogen
date
furinmedi
cleavag
describ
envelop
glycoprotein
encod
numer
evolutionarili
divers
viru
famili
includ
herp
corona
flavi
toga
borna
bunya
filo
orthomyxo
paramyxo
pneumoand
retrovirida
tabl
although
viral
furin
substrat
gener
harbour
canon
polybas
cleavag
site
time
subcellular
localis
furinmedi
activ
may
differ
substanti
viru
famili
sinc
furin
viral
glycoprotein
enter
secretori
pathway
proteolyt
activ
occur
differ
step
viral
replic
cycl
envelop
protein
virus
cleav
produc
cell
other
process
extracellular
space
entri
target
cell
figur
follow
section
highlight
characterist
select
viral
glycoprotein
process
furin
import
furinmedi
cleavag
infect
pathogen
retrovir
glycoprotein
trimer
human
immunodefici
rou
sarcoma
murin
leukaemia
virus
proteolyt
process
activ
produc
cell
figur
left
panel
case
precursor
viral
envelop
protein
env
cleav
membraneanchor
remain
associ
noncoval
interact
cleavag
occur
intracellular
compart
assembl
virion
plasma
membran
notabl
proteolyt
process
env
depend
correct
nlink
glycosyl
aberr
carbohydr
side
chain
may
result
subcellular
mistraffick
sequestr
env
like
take
advantag
redund
sever
proprotein
convertas
recognis
polybas
cleavag
motif
env
furin
shown
cleav
cell
albeit
differ
effici
notabl
vitro
cleavag
experi
use
recombin
proteas
alway
reflect
cleavag
effici
transfect
cell
rel
contribut
individu
pcsk
matur
vivo
remain
unclear
interestingli
env
harbour
second
polybas
cleavag
site
eight
amino
acid
residu
upstream
major
one
although
cleavag
site
result
fusiogen
env
speci
molecul
cleav
posit
least
case
cellcultureadapt
clone
lai
case
escap
intracellular
cleavag
may
incorpor
unprocess
precursor
bud
virion
whether
env
molecul
may
process
extracellularli
shed
furin
unknown
context
noteworthi
membranebound
plasmin
shown
convert
extracellular
howev
remain
determin
whether
plasminmedi
cleavag
result
fulli
infecti
particl
influenza
viru
hemagglutinin
ha
cleav
prime
varieti
cellular
proteas
even
bacteri
proteas
may
promot
influenza
viru
spread
cleav
ha
ha
ha
subunit
remain
link
via
disulphid
bond
form
trimer
structur
ha
bind
sialic
acid
receptor
viral
target
cell
ha
harbour
fusion
peptid
mediat
fusion
viral
cellular
endosom
membran
ha
cleavag
occur
within
produc
cell
upon
releas
virion
infect
cell
directli
prior
entri
new
target
cell
gener
rule
hemagglutinin
mammalian
low
pathogen
avian
influenza
virus
cleav
furin
usual
harbour
monoor
dibas
cleavag
site
instead
depend
trypsinlik
proteas
transmembran
proteas
serin
member
human
airway
trypsinlik
proteas
hat
express
trypsinlik
proteas
larg
restrict
respiratori
gastrointestin
tract
contrast
hemagglutinin
larg
number
highli
pathogen
avian
influenza
virus
hpaiv
cleav
furin
present
mani
cell
type
acquir
polybas
cleavag
site
upon
insert
addit
lysin
andor
arginin
residu
duplic
lysin
arginin
residu
ha
facilit
polymeras
slippag
amino
acid
encod
purinerich
codon
instead
prototyp
motif
hpaiv
harbour
suboptim
cleavag
motif
proteolyt
cleavag
site
effici
addit
posit
charg
amino
acid
upstream
cleavag
motif
present
attach
site
mask
oligosaccharid
chain
miss
notabl
subset
lowli
pathogen
avian
influenza
viru
strain
also
harbour
site
cleav
trypsinlik
proteas
hat
also
pcsk
howev
cleavag
effici
presenc
high
amount
furin
upon
mutat
glycosyl
site
ha
thu
abil
exploit
furin
effici
ha
cleavag
associ
increas
pathogen
determin
presenc
furin
consensu
target
site
also
adjac
residu
absenc
mask
oligosaccharid
chain
furin
cleav
glycoprotein
gp
marburg
viru
marv
five
ebolaviru
speci
larg
ntermin
subunit
mediat
receptor
bind
small
membraneanchor
ctermin
part
contain
fusion
viral
envelop
env
glycoprotein
precursor
green
migrat
er
golgi
complex
cleav
furin
pink
scissor
function
matur
env
glycoprotein
blue
process
env
glycoprotein
transport
cell
surfac
incorpor
assembl
viral
particl
contrast
dengu
virus
bud
er
lumen
incorpor
uncleav
premembran
protein
prm
right
panel
viru
particl
transit
secretori
pathway
virionassoci
prm
protein
cleav
furin
dark
blue
light
blue
b
prm
molecul
escap
furinmedi
cleavag
produc
cell
result
releas
immatur
partial
matur
dengu
viru
particl
case
process
also
occur
endosom
new
target
cell
upon
receptormedi
endocytosi
left
panel
human
papillomaviru
hpv
infect
right
panel
attach
heparan
sulphat
proteoglycan
induc
conform
chang
allow
proteolyt
process
minor
capsid
protein
red
furin
present
cell
surfac
furin
process
induc
structur
rearrang
allow
bind
secondari
receptor
subsequ
receptormedi
endocytosi
peptid
marv
human
pathogen
ebolaviru
speci
harbour
canon
furin
cleavag
site
contrast
gp
close
relat
reston
viru
caus
asymptomat
infect
human
process
less
effici
furin
carri
suboptim
cleavag
site
surprisingli
howev
uncleav
gp
mutant
highli
pathogen
ebola
viru
ebov
abl
mediat
infect
furinmedi
cleavag
requir
replic
cell
cultur
furthermor
ebov
mutant
lack
furin
cleavag
site
replic
effici
nonhuman
primat
show
differ
diseas
progress
lethal
compar
wildtyp
virus
thu
high
conserv
furin
cleavag
site
among
differ
ebolaviru
speci
surpris
remain
determin
whether
furinmedi
gp
process
play
role
natur
reservoir
host
virus
notabl
ebov
gp
gene
harbour
rna
edit
site
sequenc
may
express
fulllength
gp
also
solubl
form
glycoprotein
presgp
lack
ctermin
transmembran
domain
intriguingli
presgp
harbour
anoth
furin
recognit
site
cleav
matur
sgp
short
socal
peptid
ultim
releas
infect
cell
although
presgp
produc
higher
amount
gp
role
viral
replic
debat
among
other
sgp
suggest
serv
decoy
antigen
act
structur
substitut
induc
apoptosi
uninfect
lymphocyt
flavivirus
flaviviru
rna
translat
singl
larg
polyprotein
cleav
cellular
viral
proteas
structur
nonstructur
protein
viru
structur
protein
compris
envelop
protein
prm
e
incorpor
prme
heterodim
bud
virion
prm
act
chaperon
facilit
correct
fold
e
glycoprotein
mani
flavivirus
bud
lumen
er
enter
secretori
pathway
acid
milieu
transgolgi
network
tgn
furin
cleavag
site
expos
prm
cleav
matur
pr
protein
thu
furinmedi
cleavag
viral
glycoprotein
occur
incorpor
newli
form
virion
figur
right
panel
contrast
virus
hiv
whose
envelop
protein
cleav
assembl
pr
peptid
remain
associ
e
protein
virion
releas
cell
therebi
prevent
prematur
unintend
fusion
membran
produc
cell
furinmedi
prm
cleavag
essenti
replic
flavivirus
tickborn
enceph
dengu
viru
case
prm
molecul
escap
furin
process
produc
cell
result
releas
immatur
partial
matur
viral
particl
partial
matur
virion
still
infecti
sinc
low
amount
matur
suffici
mediat
fusion
target
cell
membran
furthermor
uncleav
prm
may
particip
virion
attach
target
cell
cleav
furin
entri
process
acid
milieu
endosom
figur
left
panel
rel
contribut
prm
process
viral
entri
new
target
cell
howev
remain
determin
ratio
matur
immatur
prm
depend
varieti
factor
includ
produc
cell
type
flaviviru
speci
exampl
dengu
virus
known
releas
high
amount
immatur
partial
matur
virus
like
conserv
acid
residu
within
furin
recognit
site
tabl
importantli
content
prm
viral
particl
also
affect
antibodi
recognit
consequ
antibodydepend
enhanc
dengu
viru
infect
thu
furinmedi
protein
process
may
markedli
affect
outcom
infect
furin
play
key
role
activ
envelop
glycoprotein
varieti
virus
activ
also
exploit
cleavag
viral
protein
one
exampl
cleavag
protein
papillomavirus
togeth
major
capsid
protein
minor
capsid
protein
build
viral
capsid
furin
cleavag
site
locat
close
n
terminu
highli
conserv
among
differ
human
papillomaviru
hpv
strain
cleavag
requir
viru
assembl
releas
essenti
infect
new
target
cell
exampl
lovo
cho
cell
lack
furin
express
complet
resist
infect
pseudovirus
one
highrisk
hpv
type
caus
cervic
cancer
contrast
flaviviru
prm
cleav
egress
entri
papillomaviru
seem
exclus
cleav
target
cell
model
propos
attach
papillomavirus
heparan
sulphat
proteoglycan
induc
conform
chang
expos
polybas
cleavag
site
upon
proteolyt
process
may
engag
secondari
cellular
receptor
mediat
infect
figur
right
panel
furthermor
interact
cleav
unknown
intracellular
receptor
may
requir
escap
endosom
compart
abil
escort
viral
dna
nucleu
illustr
also
nonenvelop
virus
evolv
abil
exploit
furin
relat
pcsk
purpos
anoth
nonenvelop
protein
cleav
furin
extern
core
antigen
hbeag
hepat
b
viru
hbv
cleav
hbeag
secret
infect
cell
exert
immunosuppress
effect
suggest
act
tcell
tolerogen
prevent
kill
infect
hepatocyt
cytotox
lymphocyt
contrast
uncleav
hbeag
may
opposit
effect
transport
plasma
membran
trigger
antivir
immun
respons
thu
furinmedi
cleavag
hbeag
may
affect
outcom
infect
intriguingli
han
chines
frequent
harbour
singl
nucleotid
polymorph
promot
fur
gene
associ
increas
risk
develop
persist
hbv
infect
detect
amount
hbeag
serum
polymorph
increas
bind
effici
hepat
transcript
factor
therebi
like
increas
furin
express
whether
observ
increas
hbv
persist
result
increas
hbeag
process
andor
effect
furin
remain
determin
viral
pathogen
host
continu
arm
race
although
virus
evolv
sophist
strategi
exploit
metabol
protein
synthesi
traffick
pathway
infect
cell
host
defenceless
besid
innat
adapt
immun
respons
directli
target
compon
viru
infect
cell
may
also
restrict
viral
spread
limit
avail
cellular
factor
critic
viral
replic
socal
viru
depend
factor
exampl
host
protein
restrict
replic
sever
viral
pathogen
deplet
cellular
dntp
level
furthermor
target
cellular
transcript
factor
suppress
viral
gene
express
intriguingli
accumul
evid
suggest
inhibit
viru
depend
factor
furin
repres
anoth
effici
broadli
activ
mechan
antivir
immun
aert
colleagu
found
proteaseactiv
receptor
gproteincoupl
receptor
interfer
express
furin
furinmedi
process
human
metapneumoviru
f
protein
followup
experi
reveal
harbour
r
xxxxr
motif
mediat
interact
sever
pcsk
line
solubl
cleav
r
abrog
abil
induc
calcium
signal
upon
thrombinmedi
cleavag
plasma
membran
surprisingli
howev
membranebound
pcsk
furin
fail
cleav
posit
instead
furin
trap
transgolgi
network
prevent
anterograd
transport
cell
surfac
figur
time
also
block
proteolyt
activ
furin
inhibit
exampl
matur
env
inhibitori
activ
share
paralogu
effici
cleav
furin
notabl
express
induc
proinflammatori
environ
brain
infect
individu
suffer
hivassoci
neurocognit
disord
hand
thu
furin
inhibit
may
repres
mechan
innat
immun
limit
spread
potenti
addit
furindepend
viral
pathogen
similar
inhibitori
activ
recent
describ
two
ifncinduc
gtpase
term
guanylatebind
protein
initi
describ
screen
novel
restrict
factor
hiv
shown
interfer
matur
retrovir
env
protein
followup
experi
reveal
antivir
activ
share
paralogu
protein
reduc
proteolyt
activ
amount
furin
result
cleavag
env
precursor
matur
reduc
newli
form
virion
poorli
infecti
figur
sinc
mani
viral
pathogen
reli
furin
relat
pcsk
matur
glyco
protein
exert
broad
antivir
activ
inhibit
replic
highli
pathogen
avian
influenza
measl
zika
virus
contrast
decreas
infect
virion
carri
glycoprotein
vesicular
stomat
viru
requir
proteolyt
activ
step
notabl
inhibit
furin
infect
cell
come
cost
sinc
furinmedi
process
matrix
metalloproteinas
cellular
substrat
also
reduc
presenc
increas
level
futur
experi
reveal
whether
gbpmediat
inhibit
furin
activ
may
also
prevent
develop
prolifer
certain
cancer
remark
increas
express
associ
favor
outcom
patient
suffer
melanoma
breast
cancer
thu
better
understand
cellular
mechan
regul
furin
activ
help
understand
pathogenesi
infecti
diseas
cancer
may
uncov
novel
target
therapeut
intervent
key
role
furin
pathogenesi
cancer
infecti
diseas
suitabl
therapeut
target
rais
signific
interest
sever
year
mani
laboratori
explor
possibl
limit
tumor
growth
viral
replic
bacteri
intox
reduc
amount
proteolyt
activ
furin
initi
studi
focus
peptid
protein
bind
activ
site
furin
inhibit
substrat
bind
competit
manner
exampl
variant
natur
occur
serin
proteas
inhibitor
antitrypsin
modifi
harbour
consensu
furin
cleavag
site
variant
term
antitrypsin
portland
inhibit
furin
shown
prevent
process
env
measl
viru
f
vitro
similarli
peptid
deriv
cleavag
site
influenza
viru
hemagglutinin
polyarginin
compet
natur
furin
substrat
even
exogen
addit
autoinhibitori
propeptid
furin
shown
reduc
enzymat
activ
limit
exampl
activ
breast
cancer
cell
howev
therapeut
potenti
propeptid
never
evalu
vivo
inhibitori
effect
like
limit
known
dissoci
furin
tgn
sever
approach
includ
incorpor
dinstead
lamino
acid
appli
increas
stabil
henc
efficaci
furin
inhibitor
exampl
hexadarginin
one
first
furin
inhibitor
exhibit
good
stabil
prevent
cytotox
effect
pseudomona
exotoxin
vitro
vivo
similarli
topic
applic
nonadarginin
shown
reduc
corneal
damag
mice
infect
pseudomona
aeruginosa
interestingli
also
show
direct
bactericid
activ
probabl
polycation
natur
besid
damino
acid
incorpor
amino
acid
analog
decarboxyl
arginin
mimet
amba
use
increas
stabil
peptidederiv
furin
inhibitor
furthermor
addit
chloromethyl
keton
cmk
moieti
c
terminu
polybas
cleavag
motif
proven
use
result
alkyl
activ
site
furin
irrevers
block
enzymat
activ
nevertheless
cytotox
cmkbase
inhibitor
instabl
cmk
moieti
may
limit
use
topic
applic
treatment
hpv
skin
infect
final
elucid
crystal
structur
furin
enabl
target
model
nonpeptid
inhibitor
streptaminebas
compound
upon
addit
guanidin
residu
streptamin
deriv
mimic
cation
furin
cleavag
site
inhibit
enzymat
activ
nanomolar
rang
vitro
dahm
colleagu
describ
interest
exampl
inhibitor
two
molecul
inhibitor
form
complex
furin
first
inhibitor
molecul
directli
interfer
conform
catalyt
triad
second
molecul
bind
adjac
planar
peptid
stretch
besid
stabil
subcellular
localis
furin
inhibitor
key
determin
efficaci
vivo
notabl
optim
localis
inhibitor
strongli
depend
process
event
target
therapeut
intervent
inhibit
activ
anthrax
toxin
exampl
inhibitor
need
enter
cell
well
reduc
hiv
particl
infect
inhibit
furinmedi
env
process
human
immunodefici
viru
hiv
particl
contain
function
matur
envelop
env
glycoprotein
fuse
plasma
membran
target
cell
releas
capsid
core
host
cell
cytoplasm
upon
revers
transcript
integr
retrovir
genom
viral
gene
express
initi
cytokin
eg
induc
inflammatori
state
furin
proteaseactiv
receptor
express
induc
furin
interact
trap
inact
protein
transgolgi
network
tgn
consequ
traffic
cell
surfac
usual
cleav
thrombin
induc
inflammatori
signal
pathway
moreov
product
infecti
particl
impair
reduc
furinmedi
cleavag
hiv
env
b
time
cell
infect
host
may
induc
express
interferonstimul
gene
guanylatebind
protein
protein
colocalis
furin
inhibit
proteolyt
activ
result
hiv
env
matur
impair
newli
form
viral
particl
poorli
infecti
sinc
incorpor
immatur
env
glycoprotein
ifniii
type
type
ii
interferon
stat
signal
transduc
activ
transcript
furin
cleav
toxin
precursor
cell
surfac
contrast
penetr
inhibitor
cell
essenti
prevent
matur
env
viral
glycoprotein
cleav
intracellularli
inhibitor
eg
haderiv
peptid
effici
enter
cell
other
modifi
increas
intracellular
avail
exampl
addit
decanoyl
moieti
cmk
inhibitor
increas
abil
penetr
cell
streptamin
deriv
may
particularli
promis
target
therapi
posit
guanidyl
substitu
determin
localis
inhibitor
distinct
subcellular
compart
endosom
golgi
complex
mani
inhibitor
describ
potent
reduc
furin
activ
vitro
vivo
also
inhibit
proprotein
convertas
recognis
similar
polybas
cleavag
site
limit
inher
competit
inhibitor
aim
mimick
target
sequenc
furin
may
overcom
alloster
inhibitor
bind
furinspecif
motif
outsid
activ
site
one
exampl
nanobodi
bind
ctermin
pdomain
furin
therebi
block
access
larger
substrat
activ
site
notabl
specif
bind
pdomain
furin
recognis
pcsk
instead
target
furin
protein
level
therapeut
approach
may
also
aim
target
rna
exampl
endogen
degrad
furin
mrna
andor
roquin
could
modul
interfer
express
thu
proteolyt
activ
amount
furin
howev
modul
roquin
like
offtarget
effect
endoribonucleas
also
degrad
addit
mrna
select
rnabas
approach
silenc
furin
via
shrna
fact
shrnamedi
suppress
furin
express
current
clinic
advanc
therapi
target
proteas
phase
iii
clinic
trial
patient
suffer
metastat
ewe
sarcoma
famili
tumor
esft
treat
immunotherapi
involv
silenc
furin
simultan
overexpress
gmcsf
specif
tumor
cell
extracorpor
transfect
reintroduc
socal
furin
knockdown
gmcsf
augment
fang
cancer
vaccin
also
known
vigil
gmcsf
boost
antitumor
respons
dendrit
cell
cell
knockdown
furin
prevent
proteolyt
activ
tgfb
may
otherwis
revert
benefici
effect
gmcsf
phase
ii
clinic
trial
autolog
fangvigil
vaccin
alreadi
proven
success
increas
relapsefre
surviv
ovarian
cancer
patient
day
show
limit
advers
effect
proprotein
convertas
furin
becom
attract
target
treatment
variou
infecti
noninfecti
diseas
regul
activ
numer
mammalian
bacteri
viral
protein
recent
year
sever
peptid
nonpeptid
inhibitor
develop
block
activ
bacteri
toxin
prevent
matur
viral
protein
suppress
tumor
growth
vitro
although
also
yield
promis
result
mous
model
limit
number
clinic
trial
human
one
major
challeng
redund
furin
relat
proprotein
convertas
also
recognis
polybas
cleavag
site
one
hand
select
inhibit
furin
may
benefici
limit
unwant
side
effect
due
inhibit
pcsk
hand
treatment
diseas
may
requir
simultan
inhibit
sever
pcsk
effici
block
patholog
substrat
convers
advanc
current
approach
better
understand
rel
contribut
individu
pcsk
nonphysiolog
proteolyt
protein
process
urgent
need
therapeut
intervent
need
specif
target
convertas
drive
diseas
progress
current
promis
approach
select
inhibit
shrnamedi
silenc
nanobodi
show
littl
offtarget
effect
even
select
inhibit
individu
pcsk
achiev
system
longterm
inhibit
like
detriment
effect
pcsk
requir
activ
hundr
cellular
substrat
thu
local
applic
target
treatment
tumor
topic
treatment
bacteri
viral
infect
may
feasibl
system
therapi
final
abil
tumor
cell
pathogen
evolv
resist
evas
mutat
remain
poorli
investig
exampl
sever
substrat
dengu
viru
prm
harbour
suboptim
furin
target
sequenc
may
optimis
cleavag
site
upon
therapi
enabl
suffici
cleavag
presenc
inhibitor
although
therapeut
applic
furin
inhibitor
may
full
pitfal
certainli
promis
approach
pursu
futur
studi
elucid
role
individu
pcsk
substrat
diseas
progress
better
understand
cellular
pathway
regul
furin
activ
may
uncov
addit
target
therapeut
intervent
